Yasuji Matsuoka - Publications

Nathan S. Kline Institute, Orangeburg, NY, United States 

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Toyn JH, Rowley A, Matsuoka Y, Tomita T, Imbimbo BP. γ -Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? International Journal of Alzheimer's Disease. 2013: 849128. PMID 23710414 DOI: 10.1155/2013/849128  0.374
2013 Huang Y, Li T, Eatherton A, Mitchell WL, Rong N, Ye L, Yang XJ, Jin S, Ding Y, Zhang J, Li Y, Wu Y, Jin Y, Sang Y, Cheng Z, ... ... Matsuoka Y, et al. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo. Neuropharmacology. 70: 278-86. PMID 23485401 DOI: 10.1016/j.neuropharm.2013.02.003  0.34
2013 Choi SH, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, Turner RS, Mattson MP, Bosetti F. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. Journal of Neurochemistry. 124: 59-68. PMID 23083210 DOI: 10.1111/Jnc.12059  0.369
2012 Li T, Huang Y, Jin S, Ye L, Rong N, Yang X, Ding Y, Cheng Z, Zhang J, Wan Z, Harrison DC, Hussain I, Hall A, Lee DH, Lau LF, ... Matsuoka Y, et al. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. Journal of Neurochemistry. 121: 277-86. PMID 22035227 DOI: 10.1111/j.1471-4159.2011.07560.x  0.346
2012 Minami SS, Clifford TG, Hoe HS, Matsuoka Y, Rebeck GW. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice. Neurobiology of Aging. 33: 825.e15-24. PMID 21741124 DOI: 10.1016/j.neurobiolaging.2011.05.014  0.451
2011 Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. Plos One. 6: e16259. PMID 21264226 DOI: 10.1371/Journal.Pone.0016259  0.483
2010 Minami SS, Sidahmed E, Aid S, Shimoji M, Niikura T, Mocchetti I, Rebeck GW, Prendergast JS, Dealwis C, Wetzel R, Bosetti F, Matsuoka Y, Hoe HS, Turner RS. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation. 7: 57. PMID 20920207 DOI: 10.1186/1742-2094-7-57  0.415
2009 Morales-Corraliza J, Mazzella MJ, Berger JD, Diaz NS, Choi JH, Levy E, Matsuoka Y, Planel E, Mathews PM. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice. Plos One. 4: e7134. PMID 19771166 DOI: 10.1371/Journal.Pone.0007134  0.547
2009 Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Disease and Associated Disorders. 23: 315-8. PMID 19571732 DOI: 10.1097/Wad.0B013E3181Aba61E  0.345
2009 Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Tomimoto H, Taniguchi T, Shimohama S. Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease. The American Journal of Pathology. 175: 17-24. PMID 19497998 DOI: 10.2353/Ajpath.2009.080908  0.442
2009 Wu F, Matsuoka Y, Mattson MP, Yao PJ. The clathrin assembly protein AP180 regulates the generation of amyloid-beta peptide. Biochemical and Biophysical Research Communications. 385: 247-50. PMID 19450545 DOI: 10.1016/j.bbrc.2009.05.050  0.432
2009 Loane DJ, Pocivavsek A, Moussa CE, Thompson R, Matsuoka Y, Faden AI, Rebeck GW, Burns MP. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nature Medicine. 15: 377-9. PMID 19287391 DOI: 10.1038/Nm.1940  0.65
2009 Hoe HS, Fu Z, Makarova A, Lee JY, Lu C, Feng L, Pajoohesh-Ganji A, Matsuoka Y, Hyman BT, Ehlers MD, Vicini S, Pak DT, Rebeck GW. The effects of amyloid precursor protein on postsynaptic composition and activity. The Journal of Biological Chemistry. 284: 8495-506. PMID 19164281 DOI: 10.1074/Jbc.M900141200  0.392
2009 Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen PS, Matsuoka Y. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo Neuroscience Letters. 450: 51-55. PMID 19022346 DOI: 10.1016/J.Neulet.2008.11.023  0.389
2009 Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, Jackson Roberts L, Mathews PM, Matsuoka Y, Ariga T, Yu RK, Thompson R, McDonald MP. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiology of Aging. 30: 1777-91. PMID 18258340 DOI: 10.1016/J.Neurobiolaging.2007.12.022  0.506
2008 Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, ... ... Matsuoka Y, et al. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Research. 1216: 92-103. PMID 18486110 DOI: 10.1016/J.Brainres.2008.03.079  0.63
2008 Hirata-Fukae C, Sidahmed EH, Gooskens TP, Aisen PS, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neuroscience Letters. 435: 186-9. PMID 18343582 DOI: 10.1016/J.Neulet.2008.02.032  0.534
2008 Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. The Journal of Pharmacology and Experimental Therapeutics. 325: 146-53. PMID 18199809 DOI: 10.1124/Jpet.107.130526  0.363
2008 Hoe HS, Minami SS, Makarova A, Lee J, Hyman BT, Matsuoka Y, Rebeck GW. Fyn modulation of Dab1 effects on amyloid precursor protein and ApoE receptor 2 processing. The Journal of Biological Chemistry. 283: 6288-99. PMID 18089558 DOI: 10.1074/Jbc.M704140200  0.348
2008 Yu WH, Matsuoka Y, Sziráki I, Hashim A, Lafrancois J, Sershen H, Duff KE. Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. Neurochemical Research. 33: 902-11. PMID 17999181 DOI: 10.1007/s11064-007-9533-4  0.551
2007 Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. The European Journal of Neuroscience. 26: 2458-68. PMID 17970733 DOI: 10.1111/J.1460-9568.2007.05852.X  0.476
2007 Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience : Mn. 31: 165-70. PMID 17478890 DOI: 10.1385/Jmn/31:02:165  0.561
2007 Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M, Martin B, Iyun T, Maudsley S, Clark RF, Mattson MP. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Experimental Neurology. 205: 166-76. PMID 17368447 DOI: 10.1016/J.Expneurol.2007.01.037  0.382
2007 Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 18: 293-6. PMID 17314674 DOI: 10.1097/Wnr.0B013E3280148E76  0.591
2007 Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM, Mattson MP. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiology of Disease. 26: 212-20. PMID 17306982 DOI: 10.1016/J.Nbd.2006.12.019  0.411
2006 Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, ... ... Matsuoka Y, et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. Journal of Neurochemistry. 99: 1555-63. PMID 17083447 DOI: 10.1111/J.1471-4159.2006.04178.X  0.532
2006 Hoe HS, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing Journal of Biological Chemistry. 281: 35176-35185. PMID 16951405 DOI: 10.1074/Jbc.M602162200  0.363
2005 Shimizu T, Matsuoka Y, Shirasawa T. Biological significance of isoaspartate and its repair system. Biological & Pharmaceutical Bulletin. 28: 1590-6. PMID 16141521 DOI: 10.1248/bpb.28.1590  0.456
2005 Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. An Abeta sequestration approach using non-antibody Abeta binding agents. Current Alzheimer Research. 2: 265-8. PMID 15974928 DOI: 10.2174/1567205053585774  0.598
2004 Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochemical and Biophysical Research Communications. 319: 733-7. PMID 15184044 DOI: 10.1016/J.Bbrc.2004.05.051  0.608
2003 Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiology of Disease. 14: 10-8. PMID 13678662 DOI: 10.1016/S0969-9961(03)00044-5  0.604
2003 Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, Mathews PM, Noble W, Matsuoka Y, Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 5645-9. PMID 12843267  0.663
2003 Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, ... Matsuoka Y, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 38: 555-65. PMID 12765608 DOI: 10.1016/S0896-6273(03)00259-9  0.648
2003 Baslow MH, Suckow RF, Gaynor K, Bhakoo KK, Marks N, Saito M, Saito M, Duff K, Matsuoka Y, Berg MJ. Brain damage results in down-regulation of N-acetylaspartate as a neuronal osmolyte. Neuromolecular Medicine. 3: 95-104. PMID 12728192 DOI: 10.1385/Nmm:3:2:95  0.432
2003 Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 29-33. PMID 12514198 DOI: 10.1523/Jneurosci.23-01-00029.2003  0.625
2002 Duff K, Noble W, Gaynor K, Matsuoka Y. Organotypic slice cultures from transgenic mice as disease model systems. Journal of Molecular Neuroscience : Mn. 19: 317-20. PMID 12540058 DOI: 10.1385/Jmn:19:3:317  0.626
Show low-probability matches.